Accelerating the Future of Oncology Drug Development: The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical Trials
Jia Liu(Garvan Institute of Medical Research), Anthony M. Joshua(St Vincent's Hospital Sydney), Vivek Subbiah(The University of Texas MD Anderson Cancer Center), Lesley Seymour(Queen's University), Razelle Kurzrock(Unknown), Elena Garralda(Memorial Sloan Kettering Cancer Center), Anthony W. Tolcher(South Texas Accelerated Research Therapeutics), Jacob J. Adashek(South Texas Accelerated Research Therapeutics), Sarah P. Blagden(Churchill Hospital), Natalie Cook(Manchester Academic Health Science Centre), Lin Shen(Peking University), Wafik S. El‐Deiry(Brown University), Jayesh Desai(Peter MacCallum Cancer Centre), S. Percy Ivy(National Cancer Institute), Christophe Massard(Institut Gustave Roussy), Shen Zhao(Sun Yat-sen University), Herbert H. Loong(Memorial Sloan Kettering Cancer Center), Li Zhang(Sun Yat-sen University), Takafumi Koyama(Tokyo National Hospital)
Cited by 11
Related Papers
Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009
|Cell Death and Differentiation|2008|3.3k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
|Molecular Cancer Therapeutics|2017|2.4k